The clinical trial of novel 3D Cartography-based targeted microwave focal therapy Device in men with risk Prostate Cancer started in Italy
Photo by Daniel Fazio
City of Health and Science Hospital of Turin, Italy (Azienda Ospedaliera Città della Salute e della Scienza di Torino) is starting a new clinical trial of Safety and Efficacy of a Novel 3D Cartography-based Targeted Microwave Focal Therapy Device in Men With Localized Low to Intermediate-risk Prostate Cancer.
Focal therapy (FT) for prostate cancer (PCa) is an interesting therapeutic option for localized disease with a favorable low- to intermediate-risk profile. The aim of this approach is to offer a personalized and less aggressive treatment as compared to radical treatments such as radical prostatectomy (RP) or primary radiation therapy, reducing functional morbidity while maintaining oncologic efficiency.
The patients aged 45 to 80 years old, with 10 years life expectancy who newly diagnosis of low to intermediate-risk PCa, defined by T1c or T2a clinical stage can be enrolled into this study.
All patients must have been diagnosed with transrectal or transperineal targeted and systematic biopsies performed with Koelis Trinity® system.
The clinical trial started on November 9, 2020 and will continue throughout December 30, 2021.
The recruiting facility is the A.O.U. San Giovanni Battista Molinette, Torino, TO, Italy.
For more details: https://ichgcp.net/clinical-trials-registry/NCT04627896.
